GLP-1 vision warning: Could demand be affected?
The US's Food and Drug Administration (FDA) recently ruled that GLP-1 weight-loss drugs should include warnings of their potential links to NAION, a condition that can cause vision loss. With warnings reminding users of the risks every time they buy the drugs, could this hit demand for GLP-1s?
Read more »